作者:Markian M. Stec、Yunxin Bo、Partha P. Chakrabarti、Lillian Liao、Mqhele Ncube、Nuria Tamayo、Rami Tamir、Narender R. Gavva、James J.S. Treanor、Mark H. Norman
DOI:10.1016/j.bmcl.2008.07.112
日期:2008.9
Clinical candidate AMG 517 (1) is a potent antagonist toward multiple modes of activation of TRPV1; however, it suffers from poor solubility. Analogs with various substituents at the R region of 3 were prepared to improve the solubility while maintaining the potent TRPV1 activity of 1. Compounds were identified that maintained potency, had good pharmacokinetic properties, and improved solubility relative to 1. (C) 2008 Elsevier Ltd. All rights reserved.